Intellijoint Surgical, based in Kitchener, Ontario, Canada, is celebrating its official launch in Japan, with Dr. Toshiaki Okura becoming the first surgeon in the country to use Intellijoint HIP®, a surgeon-controlled navigation system that offers real-time measurements for optimal implant alignment and positioning.
Intellijoint Surgical Launches in Japan
“We’ve been eagerly anticipating this launch in Japan and it’s finally here. We are so proud that our Intellijoint HIP navigation technology will benefit the great people of Japan,” says Armen Bakirtzian, company co-founder and CEO. “Joint pain impacts people all over the world and it’s our mission to provide every surgeon with the best tools to optimize patient outcomes.”
With five hip replacement surgeries in Japan and counting, Intellijoint received rave reviews from surgeons. Intellijoint and its local distribution partner, Japan Medical Dynamic Marketing, are excited by this promising start.
According to Intellijoint, Japanese surgeons are saying that it is easy to see the angle numbers for inclination and anteversion because the screen is bigger than other systems they have used. These surgeons say that they appreciate that Intellijoint HIP is larger and easier to read while they are in the middle of cases. The Japanese surgeons are also saying that Intellijoint’s camera reaction is better and more responsive than others they have used—and it allows for easy registration.
Armen Bakirtzian told OTW, “Our one-year goal is simple: we want to show surgeons and patients in Japan the many benefits of Intellijoint’s technology. And doing that will enable our continued growth. Japan is a very important market for us and this next year is about getting our product in as many surgeon’s hands, so they experience the Intellijoint difference firsthand.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.